780 related articles for article (PubMed ID: 31128009)
1. Clinical research on stereotactic radiosurgery combined with epithermal growth factor tyrosine kinase inhibitors in the treatment of brain metastasis of non-small cell lung cancer.
Jia F; Cheng X; Zeng H; Miao J; Hou M
J BUON; 2019; 24(2):578-584. PubMed ID: 31128009
[TBL] [Abstract][Full Text] [Related]
2. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses.
Zhao B; Wang Y; Wang Y; Chen W; Zhou L; Liu PH; Kong Z; Dai C; Wang Y; Ma W
Aging (Albany NY); 2020 Jul; 12(14):14244-14270. PubMed ID: 32669477
[TBL] [Abstract][Full Text] [Related]
5. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.
Magnuson WJ; Yeung JT; Guillod PD; Gettinger SN; Yu JB; Chiang VL
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):673-9. PubMed ID: 27034176
[TBL] [Abstract][Full Text] [Related]
6. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.
Doherty MK; Korpanty GJ; Tomasini P; Alizadeh M; Jao K; Labbé C; Mascaux CM; Martin P; Kamel-Reid S; Tsao MS; Pintilie M; Liu G; Bradbury PA; Feld R; Leighl NB; Chung C; Shepherd FA
Radiother Oncol; 2017 May; 123(2):195-202. PubMed ID: 28363487
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.
Zhai X; Li W; Li J; Jia W; Jing W; Tian Y; Xu S; Li Y; Zhu H; Yu J
Radiat Oncol; 2021 Dec; 16(1):233. PubMed ID: 34865626
[TBL] [Abstract][Full Text] [Related]
8. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer.
Cai L; Zhu JF; Zhang XW; Lin SX; Su XD; Lin P; Chen K; Zhang LJ
J Neurooncol; 2014 Nov; 120(2):423-30. PubMed ID: 25098700
[TBL] [Abstract][Full Text] [Related]
9. [Timing of Whole Brain Radiotherapy on Survival of Patients with EGFR-mutated
Non-small Cell Lung Cancer and Brain Metastases].
Liu G; Zhang X; Tian C; Xia G; Liu P; Zhang Q; Li X; Zhang H; Qin N; Wang J; Zhang S
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):501-7. PubMed ID: 27561798
[TBL] [Abstract][Full Text] [Related]
10. Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors.
Lee JH; Chen HY; Hsu FM; Chen JS; Liao WY; Shih JY; Yu CJ; Chen KY; Tsai TH; Yang JC
Oncologist; 2019 Dec; 24(12):e1417-e1425. PubMed ID: 31127020
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant.
Zhao L; Cai X; Chen D; Ye X; Gao M; Lu L; Su H; Su M; Hou M; Xie C
Radiat Oncol; 2019 Dec; 15(1):3. PubMed ID: 31892337
[TBL] [Abstract][Full Text] [Related]
12. Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer.
Liu K; Jiang G; Zhang A; Li Z; Jia J
BMC Cancer; 2020 Jan; 20(1):76. PubMed ID: 32000711
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis.
Chen Y; Wei J; Cai J; Liu A
BMC Cancer; 2019 Aug; 19(1):793. PubMed ID: 31399067
[TBL] [Abstract][Full Text] [Related]
14. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
Jiang T; Zhang Y; Li X; Zhao C; Chen X; Su C; Ren S; Yang N; Zhou C
Eur J Cancer; 2019 Nov; 121():98-108. PubMed ID: 31569068
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery.
Yang WC; Xiao F; Shih JY; Ho CC; Chen YF; Tseng HM; Chen KY; Liao WY; Yu CJ; Yang JC; Kuo SH; Cheng JC; Yang PC; Hsu FM
Radiother Oncol; 2018 Feb; 126(2):368-374. PubMed ID: 29111173
[TBL] [Abstract][Full Text] [Related]
16. EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases.
Jiang T; Su C; Li X; Zhao C; Zhou F; Ren S; Zhou C; Zhang J
J Thorac Oncol; 2016 Oct; 11(10):1718-28. PubMed ID: 27237825
[TBL] [Abstract][Full Text] [Related]
17. Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis.
Yan W; Liu Y; Li J; Han A; Kong L; Yu J; Zhu H
Radiat Oncol; 2019 Sep; 14(1):168. PubMed ID: 31521171
[TBL] [Abstract][Full Text] [Related]
18. Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.
Miyawaki E; Kenmotsu H; Mori K; Harada H; Mitsuya K; Mamesaya N; Kawamura T; Kobayashi H; Nakashima K; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Endo M; Nakasu Y; Gon Y; Takahashi T
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):604-613. PubMed ID: 30851347
[TBL] [Abstract][Full Text] [Related]
19. Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis.
Hyun DG; Choi CM; Lee DH; Kim SW; Yoon S; Kim WS; Ji W; Lee JC
PLoS One; 2020; 15(4):e0231546. PubMed ID: 32298306
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases.
Ke SB; Qiu H; Chen JM; Shi W; Chen YS
Curr Med Sci; 2018 Dec; 38(6):1062-1068. PubMed ID: 30536070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
